Stockreport

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC [Yahoo! Finance]

Cognition Therapeutics, Inc.  (CGTX) 
PDF Cognition Therapeutics, Inc. Thu, January 30, 2025 at 1:30 PM GMT+1 5 min read In This Article CGTX Cognition Therapeutics, Inc. – Study demonstrated strong [Read more]